CommercialPrior AuthHigh impact
Collagenase Clostridium Histolyticum (Xiaflex) (CPB 1061, reviewed 2025-09-17)
Aetna·Orthopedics, Plastic Surgery, Urology·Medical Policy
Effective date
Sep 17, 2025
We identified it
Aug 13, 2026
Summary
Aetna updated its Xiaflex (collagenase clostridium histolyticum) coverage policy effective September 17, 2025, defining strict medical necessity criteria for Dupuytren's contracture and Peyronie's disease treatment. The policy establishes specific authorization requirements including provider specialty credentials, injection limits (3 per cord for Dupuytren's; 8 total for Peyronie's), and clinical measurement thresholds (20° contracture, positive tabletop test for Dupuytren's; 30-90° curvature for Peyronie's). Billing teams must implement prior authorization workflows requiring documented clinical criteria before claims will be processed.
Action Required
REQUIREMENTS:
Effective immediately (September 17, 2025):
1. BILLING TEAM: Update claims submission system to require prior authorization for HCPCS code J0775 (collagenase clostridium histolyticum) on all Aetna commercial plans. Do NOT process claims without documented prior auth approval.
2. PRIOR AUTH TEAM: Create authorization request template requiring:
- For Dupuytren's contracture: Documentation of (a) palpable cord location, (b) contracture angle ≥20°, (c) positive tabletop test result, (d) patient age ≥18 years, (e) number of injections requested (max 3 per cord)
- For Peyronie's disease: Documentation of (a) stable disease ≥3 months, (b) palpable plaque with 30-90° curvature, (c) intact erectile function, (d) patient age ≥18 years, (e) total lifetime injections to date, (f) current injection count (max 8 lifetime total)
3. BILLING TEAM: Flag and deny any claims for:
- Cosmetic use of Xiaflex (cellulite reduction) - explicitly non-covered
- More than 3 injections per cord (Dupuytren's) - exceeds policy limit
- More than 8 lifetime injections (Peyronie's) - exceeds policy limit
- Peyronie's plaques with <30° or ≥90° curvature - outside medical necessity criteria
- Ultrasound guidance for Dupuytren's injection - experimental/not covered
- Hand therapy post-treatment - experimental/not covered
- Treatment without provider credentials (hand surgery/orthopedics with injection experience for Dupuytren's; urology with XIAFLEX REMS certification for Peyronie's)
4. PROVIDERS/CLINICAL STAFF: Educate prescribing providers that:
- Dupuytren's injections must be administered by providers experienced in hand injection procedures
- Peyronie's injections require provider completion of XIAFLEX REMS program training
- Treatment cycles must follow 4-week intervals (Dupuytren's) or 6-week intervals between treatment cycles (Peyronie's)
5. FRONT DESK/PATIENT ACCESS: When scheduling Xiaflex procedures, verify with patient that prior authorization has been obtained before appointment confirmation.
CONSEQUENCES: Claims submitted without prior authorization or exceeding injection limits will be denied. Retroactive authorization is not guaranteed. Patients may receive balance bills if claims are denied due to lack of prior auth.